Updates on Molecular Targeted Therapies for CNS Tumors
The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood–brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Assuntos: | |
| Acesso em linha: | ONIX_20230911_9783036585284_97 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869518993043226624 |
|---|---|
| collection | Directory of Open Access Books |
| description | The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood–brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular targets must be key drivers in the growth and progression of CNS tumors. Numerous potentially efficacious therapies have failed in randomized clinical trials due to other factors, including subclonal genetic intratumoral heterogeneity (particularly within malignant gliomas), epigenetic heterogeneity, and failure to target important factors involved in the tumor microenvironment. Developing effective targeted therapies requires a thorough fundamental understanding of the genetic and epigenetic factors driving tumor progression, the interactions between CNS tumor cells and the tumor microenvironment, and the key mechanisms of tumor treatment resistance. In this Special Issue, experts in the field of CNS tumors will highlight the most promising molecular targets in the development of treatments for patients with CNS tumors. |
| format | Online |
| id | doab-20.500.12854ir-113964 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1139642024-03-31T13:10:39Z Updates on Molecular Targeted Therapies for CNS Tumors Pan, Edward glioblastoma molecular classification ERK/MAPK pathway PI3K/PTEN pathway receptor tyrosine kinase EGFR PDGFRA FGFR3 MET EPHB2 NF1 immunotherapy glioblastoma blood–brain barrier central nervous system T cells T lymphocytes PCNSL CNS lymphoma methotrexate novel therapies novel therapeutics neurofibromatosis low grade glioma plexiform neurofibroma vestibular schwannoma glioma tumor mutation burden neoantigen immune score germline mutation antigen processing and presentation ependymoma subependymoma RELA YAP1 ZFTA PFA PFB MYCN Group A Group B myxopapillary targeted therapy diffuse midline gliomas molecular targets potential therapy development intraparenchymal metastases CNS disease metastatic disease tyrosine kinase inhibitors monoclonal antibodies Warburg effect mass spectrometry isotope labeling cancer metabolism pediatric brain tumor adenosine tumor microenvironment A2AAR antagonist immune evasion adenosine receptors bevacizumab temozolomide progression biomarker neoplastic meningitis leptomeningeal chemotherapy radiotherapy intrathecal GBM U87MG A172 Metformin LPS antioxidant cell cycle arrest apoptosis low-grade glioma preclinical models IDH-mutant glioma patient avatars methylation methylomics G-CIMP MGMT DNMT ATRX H3K27M CpG island tumor suppressor methyltransferases histone acetylation brain tumor brain metastasis lung cancer lung malignancy progression-free survival epidermal growth factor receptor lung carcinoma molecular therapy whole-brain radiation therapy stereotactic radiosurgery KIF11 n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood–brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular targets must be key drivers in the growth and progression of CNS tumors. Numerous potentially efficacious therapies have failed in randomized clinical trials due to other factors, including subclonal genetic intratumoral heterogeneity (particularly within malignant gliomas), epigenetic heterogeneity, and failure to target important factors involved in the tumor microenvironment. Developing effective targeted therapies requires a thorough fundamental understanding of the genetic and epigenetic factors driving tumor progression, the interactions between CNS tumor cells and the tumor microenvironment, and the key mechanisms of tumor treatment resistance. In this Special Issue, experts in the field of CNS tumors will highlight the most promising molecular targets in the development of treatments for patients with CNS tumors. 2023-09-11T12:12:44Z 2023-09-11T12:12:44Z 2023 book ONIX_20230911_9783036585284_97 9783036585284 9783036585291 https://directory.doabooks.org/handle/20.500.12854/113964 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/7808 https://mdpi.com/books/pdfview/book/7808 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-8529-1 10.3390/books978-3-0365-8529-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036585284 9783036585291 368 open access |
| spellingShingle | glioblastoma molecular classification ERK/MAPK pathway PI3K/PTEN pathway receptor tyrosine kinase EGFR PDGFRA FGFR3 MET EPHB2 NF1 immunotherapy glioblastoma blood–brain barrier central nervous system T cells T lymphocytes PCNSL CNS lymphoma methotrexate novel therapies novel therapeutics neurofibromatosis low grade glioma plexiform neurofibroma vestibular schwannoma glioma tumor mutation burden neoantigen immune score germline mutation antigen processing and presentation ependymoma subependymoma RELA YAP1 ZFTA PFA PFB MYCN Group A Group B myxopapillary targeted therapy diffuse midline gliomas molecular targets potential therapy development intraparenchymal metastases CNS disease metastatic disease tyrosine kinase inhibitors monoclonal antibodies Warburg effect mass spectrometry isotope labeling cancer metabolism pediatric brain tumor adenosine tumor microenvironment A2AAR antagonist immune evasion adenosine receptors bevacizumab temozolomide progression biomarker neoplastic meningitis leptomeningeal chemotherapy radiotherapy intrathecal GBM U87MG A172 Metformin LPS antioxidant cell cycle arrest apoptosis low-grade glioma preclinical models IDH-mutant glioma patient avatars methylation methylomics G-CIMP MGMT DNMT ATRX H3K27M CpG island tumor suppressor methyltransferases histone acetylation brain tumor brain metastasis lung cancer lung malignancy progression-free survival epidermal growth factor receptor lung carcinoma molecular therapy whole-brain radiation therapy stereotactic radiosurgery KIF11 n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Updates on Molecular Targeted Therapies for CNS Tumors |
| title | Updates on Molecular Targeted Therapies for CNS Tumors |
| title_full | Updates on Molecular Targeted Therapies for CNS Tumors |
| title_fullStr | Updates on Molecular Targeted Therapies for CNS Tumors |
| title_full_unstemmed | Updates on Molecular Targeted Therapies for CNS Tumors |
| title_short | Updates on Molecular Targeted Therapies for CNS Tumors |
| title_sort | updates on molecular targeted therapies for cns tumors |
| topic | glioblastoma molecular classification ERK/MAPK pathway PI3K/PTEN pathway receptor tyrosine kinase EGFR PDGFRA FGFR3 MET EPHB2 NF1 immunotherapy glioblastoma blood–brain barrier central nervous system T cells T lymphocytes PCNSL CNS lymphoma methotrexate novel therapies novel therapeutics neurofibromatosis low grade glioma plexiform neurofibroma vestibular schwannoma glioma tumor mutation burden neoantigen immune score germline mutation antigen processing and presentation ependymoma subependymoma RELA YAP1 ZFTA PFA PFB MYCN Group A Group B myxopapillary targeted therapy diffuse midline gliomas molecular targets potential therapy development intraparenchymal metastases CNS disease metastatic disease tyrosine kinase inhibitors monoclonal antibodies Warburg effect mass spectrometry isotope labeling cancer metabolism pediatric brain tumor adenosine tumor microenvironment A2AAR antagonist immune evasion adenosine receptors bevacizumab temozolomide progression biomarker neoplastic meningitis leptomeningeal chemotherapy radiotherapy intrathecal GBM U87MG A172 Metformin LPS antioxidant cell cycle arrest apoptosis low-grade glioma preclinical models IDH-mutant glioma patient avatars methylation methylomics G-CIMP MGMT DNMT ATRX H3K27M CpG island tumor suppressor methyltransferases histone acetylation brain tumor brain metastasis lung cancer lung malignancy progression-free survival epidermal growth factor receptor lung carcinoma molecular therapy whole-brain radiation therapy stereotactic radiosurgery KIF11 n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | glioblastoma molecular classification ERK/MAPK pathway PI3K/PTEN pathway receptor tyrosine kinase EGFR PDGFRA FGFR3 MET EPHB2 NF1 immunotherapy glioblastoma blood–brain barrier central nervous system T cells T lymphocytes PCNSL CNS lymphoma methotrexate novel therapies novel therapeutics neurofibromatosis low grade glioma plexiform neurofibroma vestibular schwannoma glioma tumor mutation burden neoantigen immune score germline mutation antigen processing and presentation ependymoma subependymoma RELA YAP1 ZFTA PFA PFB MYCN Group A Group B myxopapillary targeted therapy diffuse midline gliomas molecular targets potential therapy development intraparenchymal metastases CNS disease metastatic disease tyrosine kinase inhibitors monoclonal antibodies Warburg effect mass spectrometry isotope labeling cancer metabolism pediatric brain tumor adenosine tumor microenvironment A2AAR antagonist immune evasion adenosine receptors bevacizumab temozolomide progression biomarker neoplastic meningitis leptomeningeal chemotherapy radiotherapy intrathecal GBM U87MG A172 Metformin LPS antioxidant cell cycle arrest apoptosis low-grade glioma preclinical models IDH-mutant glioma patient avatars methylation methylomics G-CIMP MGMT DNMT ATRX H3K27M CpG island tumor suppressor methyltransferases histone acetylation brain tumor brain metastasis lung cancer lung malignancy progression-free survival epidermal growth factor receptor lung carcinoma molecular therapy whole-brain radiation therapy stereotactic radiosurgery KIF11 n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20230911_9783036585284_97 |